Anzeige
Mehr »
Dienstag, 25.11.2025 - Börsentäglich über 12.000 News
Goldrausch 2.0: 60% Insideranteil - warum dieser Gold-Explorer als Geheimtipp gilt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EQA8 | ISIN: IT0005549255 | Ticker-Symbol: X74
Frankfurt
22.10.25 | 09:59
1,360 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMD INTERNATIONAL MEDICAL DEVICES SPA Chart 1 Jahr
5-Tage-Chart
IMD INTERNATIONAL MEDICAL DEVICES SPA 5-Tage-Chart

Aktueller Chart IMD INTERNATIONAL MEDICAL DEVICES Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
IMD INTERNATIONAL MEDICAL DEVICES SPA-Investoren interessieren sich auch für diese Wertpapiere
Heartflow, Inc.: Heartflow Announces FDA 510(k) Clearance and Launch of Next Generation Heartflow Plaque Analysis PlatformMOUNTAIN VIEW, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it has received...
► Artikel lesen
Heartflow, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesMOUNTAIN VIEW, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the closing of its...
► Artikel lesen
Heartflow, Inc. Announces Pricing of Upsized Initial Public OfferingMOUNTAIN VIEW, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the pricing of its...
► Artikel lesen
Castle Biosciences, Inc.: New Data Confirms Performance of DecisionDx-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node PositivityFRIENDSWOOD, Texas, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data...
► Artikel lesen
SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 millionSTOCKHOLM, Nov. 7, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that SciBase...
► Artikel lesen
Castle Biosciences, Inc.: Castle Biosciences Reports Third Quarter 2025 ResultsDelivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 Q3 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®)...
► Artikel lesen
GeneDx to Participate in Upcoming Investor ConferencesGeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences: Stifel...
► Artikel lesen
Rackspace US, Inc.: Rackspace Technology und Sema4.ai stellen die erste skalierbare KI-Agent-Lösung für Unternehmen vorDie unternehmensgerechte Lösung schließt die Lücke zwischen KI-Experimenten und umfassender TransformationSAN ANTONIO, June 18, 2025®) und die Anwendungsmanagement-Expertise von Rackspace mit der fortschrittlichen...
► Artikel lesen
Rackspace US, Inc.: Rackspace Technology and Sema4.ai Launch Industry's First Scalable Enterprise AI Agent SolutionEnterprise-ready Solution Bridges the Gap from AI Experimentation to Full-Scale TransformationSAN ANTONIO, June 18, 2025) services and Rackspace's application management expertise with Sema4.ai's advanced...
► Artikel lesen